Healthcare provider profile · identity verified

Christopher Mendiola, PAC

Physician Assistant · SAN ANTONIO, TX · NPI 1689029308

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Fluticasone Propionate	Fluticasone Propionate	134	60
Amlodipine Besylate	Amlodipine Besylate	107	46
Gabapentin	Gabapentin	85	29
Montelukast Sodium	Montelukast Sodium	85	28
Atorvastatin Calcium	Atorvastatin Calcium	80	44
Furosemide	Furosemide	80	24
Losartan Potassium	Losartan Potassium	80	37
Albuterol Sulfate Hfa	Albuterol Sulfate	78	28
Pantoprazole Sodium	Pantoprazole Sodium	73	35
Rosuvastatin Calcium	Rosuvastatin Calcium	73	36
Lisinopril	Lisinopril	72	36
Ozempic	Semaglutide	67	25
Levothyroxine Sodium	Levothyroxine Sodium	65	27
Farxiga	Dapagliflozin Propanediol	52	15
Tramadol Hcl	Tramadol Hcl	46	12
Diclofenac Sodium	Diclofenac Sodium	45	18
Mounjaro	Tirzepatide	45	suppressed
Sertraline Hcl	Sertraline Hcl	45	14
Baclofen	Baclofen	44	21
Metoprolol Succinate	Metoprolol Succinate	42	21
Hydrochlorothiazide	Hydrochlorothiazide	40	18
Trazodone Hcl	Trazodone Hcl	38	16
Spironolactone	Spironolactone	36	11
Metformin Hcl	Metformin Hcl	34	22
Tamsulosin Hcl	Tamsulosin Hcl	34	19
Esomeprazole Magnesium	Esomeprazole Magnesium	33	12
Hydroxyzine Hcl	Hydroxyzine Hcl	31	18
Metformin Hcl Er	Metformin Hcl	30	17
Acetaminophen-Codeine	Acetaminophen With Codeine	29	suppressed
Carvedilol	Carvedilol	29	17
Enalapril Maleate	Enalapril Maleate	29	suppressed
Omeprazole	Omeprazole	29	13
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Simvastatin	Simvastatin	28	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Naproxen	Naproxen	26	suppressed
Ibuprofen	Ibuprofen	25	17
Alendronate Sodium	Alendronate Sodium	24	suppressed
Meloxicam	Meloxicam	23	suppressed
Potassium Chloride	Potassium Chloride	23	suppressed
Famotidine	Famotidine	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Pregabalin	Pregabalin	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Tradjenta	Linagliptin	18	suppressed
Clobetasol Propionate	Clobetasol Propionate	17	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	12
Eliquis	Apixaban	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	15	suppressed
Trintellix	Vortioxetine Hydrobromide	15	suppressed
Celecoxib	Celecoxib	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	12
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Glipizide	Glipizide	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Atrovent Hfa	Ipratropium Bromide	12	suppressed
Folic Acid	Folic Acid	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Topiramate	Topiramate	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Finasteride	Finasteride	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error